Series
|
Year
|
Origin
|
N
|
Stages
|
Further description
|
---|
Cortes-Funes et al. [10]
|
2005
|
Spain
|
83
|
Advanced
|
Failing 1st line/TKI therapy
|
Marchetti et al. [15]
|
2005
|
Italy
|
860
|
Stage I-II-III
|
Resection specimen
|
Rosell et al. [19]
|
2009
|
Spain
|
2105
|
Advanced
|
-
|
Penzel et al. [21]
|
2011
|
Germany
|
1047
|
All
|
-
|
Helland et al. [16]
|
2011
|
Norway
|
240
|
Stage I-II-III
|
Resection specimen
|
Vincenten et al. [20]
|
2012
|
Netherlands
|
810
|
All
|
-
|
Smits et al. [14]
|
2012
|
Netherlands
|
778
|
Advanced
|
-
|
Leary et al. [12]
|
2012
|
England
|
144
|
All
|
-
|
Pennycuick et al. [11]
|
2012
|
England
|
215
|
All
|
Non-squamous NSCLC
|
Vaguliene et al. [13]
|
2012
|
Lithuania
|
103
|
Advanced
|
Non-squamous NSCLC
|
Cadranel et al. [22]
|
2012
|
France
|
522
|
All
|
Failing 1st line/TKI therapy
|
This series
|
2012
|
Belgium
|
297
|
Advanced
|
ESMO guideline selected
|
- N: number; TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; ESMO: European Society of Medical Oncology.